Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy
- 16 April 2026
- journal article
- Published by American Society of Hematology in Blood
- Vol. 147 (16) , 1857-1862
Abstract
Quadruplet (QUAD) induction and autologous stem cell transplantation (ASCT) leads to high rates of measurable residual disease (MRD) negativity with improved outcomes in multiple myeloma (MM). The t(11;14) confers unique biology and different kinetics of treatment response. We analyzed MRD trajectories of patients treated with QUAD/ASCT and MRD-adapted post-ASCT management. Of the 302 patients assessed, 47 (16%) had t(11;14)+ MM. Median follow-up was 45.8 months. MRD negativity at <10−5 level (MRD <10−5) for t(11;14)+ vs t(11;14)− MM was 9% vs 31%, 36% vs 59%, and 53% vs 75% after induction, after ASCT, and any time on treatment, respectively. The rates of sustained MRD negativity <10−5 (S-MRD <10−5) were 38% vs 46%. Median time to MRD <10−5 was 13.6 vs 7.7 months for t(11;14)+ vs t(11;14)− MM, respectively. Progression-free survival (PFS) was superior for patients with t(11;14)+ MM, with 4-year PFS rates of 90% vs 72%. In multivariable analysis, S-MRD <10−5 were associated with reduced risk of progression or death, with no progression seen in those with t(11;14)+ MM who achieved S-MRD <10−5. In the setting of QUAD/ASCT therapy and MRD-adapted post-ASCT management, t(11;14)+ newly diagnosed MM is associated with improved prognosis despite slow conversion to MRD negativity.Keywords
This publication has 18 references indexed in Scilit:
- Updated Interim Results of Sonrotoclax + Dexamethasone in Patients With t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM): An All-Oral TreatmentClinical Lymphoma Myeloma and Leukemia, 2025
- T(11;14) with multiple myeloma: Standard risk survival but slow and poor responseAnnals of Hematology, 2024
- OA-46 Phase II Clinical Trial of Minimal Residual Disease Response-Adapted Deferral of Transplantation in Dysproteinemia (MILESTONE)Clinical Lymphoma Myeloma and Leukemia, 2024
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trialThe Lancet Oncology, 2024
- Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaNew England Journal of Medicine, 2024
- Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trialThe Lancet Haematology, 2023
- Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trialThe Lancet Haematology, 2023
- Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trialThe Lancet Oncology, 2020
- International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trialsLeukemia, 2020
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaThe Lancet Oncology, 2016